SAGE US78667J1088

Report

Delayed Nasdaq - 04:00 2022-09-29 pm EDT
39.60	USD		-1.57%

09/19	Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone	BU
09/12	Transcript : Sage Therapeutics, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 03:40 PM	CI
09/05	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	AQ

Most relevant news about SAGE THERAPEUTICS, INC.

09/19	Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating ..	BU
09/12	Transcript : Sage Therapeutics, Inc. Presents at Morgan Stanley 20th Annual G..	CI
09/05	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	AQ
09/02	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	BU
08/03	Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating	MT
08/03	Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra..	MT
08/03	Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin..	MT
08/02	Transcript : Sage Therapeutics, Inc., Q2 2022 Earnings Call, Aug 02, 2022	CI
08/02	Sage Therapeutics Widens Q2 Net Loss as Revenue Declines	MT
08/02	Sage Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months ..	CI
08/02	Sage Therapeutics : Announces Second Quarter 2022 Financial Results and Highlights Pipelin..	PU
08/02	Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeli..	BU
08/01	Sage Therapeutics to Present at Upcoming August Investor Conferences	BU
07/19	Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2,..	BU
07/14	Sage Therapeutics : IF YOU DO NOT OBJECT TO THE PROPOSED SETTLEMENT, OR THE AGREED-TO ATTO..	PU

All news about SAGE THERAPEUTICS, INC.

09/19	Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating ..	BU
09/12	Transcript : Sage Therapeutics, Inc. Presents at Morgan Stanley 20th Annual G..	CI
09/05	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	AQ
09/02	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	BU
08/03	Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating	MT
08/03	Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra..	MT
08/03	Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin..	MT
08/02	Transcript : Sage Therapeutics, Inc., Q2 2022 Earnings Call, Aug 02, 2022	CI
08/02	Sage Therapeutics Widens Q2 Net Loss as Revenue Declines	MT
08/02	SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..	AQ

News in other languages on SAGE THERAPEUTICS, INC.

08/02	Sage Therapeutics creuse sa perte nette au 2e trimestre et voit ses revenus diminuer
08/02	Sage Therapeutics, Inc. annonce ses résultats financiers pour le deuxième trimestre et ..
06/13	Sage Therapeutics, Inc. fournit une mise à jour sur la demande de nouveau médicament po..
06/01	Le médicament de Sage-Biogen améliore les symptômes dans une étude sur la dépression po..
06/01	Sage Therapeutics et Biogen annoncent que l'étude de phase 3 SKYLARK sur la Zuranolone ..
06/01	USA-Les valeurs à suivre à Wall Street (actualisé)
05/09	Achat d'initiés : Sage Therapeutics
05/03	Sage Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars..
05/03	Sage Therapeutics nomme Mark Pollack au poste de vice-président principal des affaires ..
05/02	Sage et Biogen commencent à soumettre à la FDA américaine une demande d'autorisation de..

Analyst Recommendations on SAGE THERAPEUTICS, INC.

08/03	Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating	MT
08/03	Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra..	MT
08/03	Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin..	MT
07/11	SVB Securities Adjusts Sage Therapeutics' Price Target to $40 from $50, Keeps Market Pe..	MT
07/01	Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcar..	MT

Press releases

09/19	Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating ..	BU
09/05	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	AQ
09/02	Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference	BU
08/02	SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..	AQ
08/02	Sage Therapeutics : Announces Second Quarter 2022 Financial Results and Highlights Pipelin..	PU

Upcoming event on SAGE THERAPEUTICS, INC.

11/02/22

Upcoming sector events

10/27/22	GILEAD SCIENCES, INC. : Q3 2022 Earnings Release (Projected)
11/02/22	VERTEX PHARMACEUTICALS INCORPORATED : Q3 2022 Earnings Release (Projected)
11/03/22	WUXI APPTEC CO., LTD. : Q3 2022 Earnings Release (Projected)
11/07/22	BIONTECH SE : Q3 2022 Earnings Release

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Bio Therapeutic Drugs